Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04248699 · ClinicalTrials.gov registry record · NA
Lumenato Nutritional Supplement on Skin Appearance
A NA study of Skin, sponsored by LycoRed.
- Completed
- Registry status
- NA
- Development phase
- 72
- Enrollment target
- 1
- Study location
NCT04248699 is a NA study of Skin that has completed, run by LycoRed. The registered enrollment target is 72 participants, above the 52-participant average among 5 other Skin trials with a reported enrollment target (38% higher). The trial reports 1 study location across 1 state.
The verdict
NCT04248699, a NA study of Skin, has completed, sponsored by LycoRed.
- COMPLETED
- Registry status
- NA
- Development phase
- 72 participants
- Enrollment target
- 1
- Study location
Study Summary
This 12-week study is an open-label study assessing the perceived effectiveness of the Lycored Lumenato supplement on skin health and appearance.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Lumenato
Study Locations (1)
Florida
- o ObvioHealth - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2020-01-14 |
| Est. Completion | 2020-07-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04248699
The ClinicalTrials.gov registry entry for NCT04248699 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 52-participant average among 5 other Skin trials with a reported enrollment target (38% higher). The listed sponsor is LycoRed, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Skin appearing as the primary indexed condition, and to 1 intervention - of which Lumenato is the first listed.
NCT04248699 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT04248699 about?
NCT04248699 is a clinical study titled "Lumenato Nutritional Supplement on Skin Appearance". This 12-week study is an open-label study assessing the perceived effectiveness of the Lycored Lumenato supplement on skin health and appearance.
What is the current status of trial NCT04248699?
This trial is currently completed. It is a NA study. The enrollment target is 72 participants. The study started on 2020-01-14. Estimated completion is 2020-07-08.
What conditions does trial NCT04248699 study?
This clinical trial studies the following conditions: Skin.
What interventions are being tested in trial NCT04248699?
The interventions under investigation include: Lumenato (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT04248699?
This trial is sponsored by LycoRed, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04248699 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Skin
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
See the Impact Beem's Blue Light Therapy Has on Your Skin Health!
RECRUITING · NA
-
The Effect of Topical Almond Oil vs. Topical Retinol on The Appearance of Facial Wrinkles
COMPLETED · NA
-
A Clinical Study to Evaluate the Efficacy and Consumer Perception of Lumenato
COMPLETED · NA
-
Trial of Ixazomib for Kaposi Sarcoma
RECRUITING · Phase 2
-
In Vivo Cross-Modal Imaging of Skin
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.